{Reference Type}: Observational Study
{Title}: Real-world data of AML in Japan: results of JALSG clinical observational study-11 (JALSG-CS-11).
{Author}: Usuki K;Ohtake S;Honda S;Matsuda M;Wakita A;Nawa Y;Takase K;Maeda A;Sezaki N;Yokoyama H;Takada S;Hirano D;Tomikawa T;Sumi M;Yano S;Handa H;Ota S;Fujita H;Fujimaki K;Mugitani A;Kojima K;Kajiguchi T;Fujimoto K;Asou N;Usui N;Ishikawa Y;Katsumi A;Matsumura I;Kiyoi H;Miyazaki Y;
{Journal}: Int J Hematol
{Volume}: 119
{Issue}: 1
{Year}: 2024 Jan 28
{Factor}: 2.319
{DOI}: 10.1007/s12185-023-03677-w
{Abstract}: This report covers acute myeloid leukemia (AML) results from a multicenter, prospective observational study of AML, myelodysplastic syndromes, and chronic myelomonocytic leukemia in Japan. From August 2011 to January 2016, 3728 AML patients were registered. Among them, 42% were younger than 65, and the male-to-female ratio was 1.57:1. With a median follow-up time of 1807 days (95% confidence interval [CI]: 1732-1844 days), the estimated 5-year overall survival (OS) rate in AML patients (n = 3707) was 31.1% (95% CI: 29.5-32.8%). Trial-enrolled patients had a 1.7-fold higher OS rate than non-enrolled patients (5-year OS, 58.9% [95% CI: 54.5-63.1%] vs 35.5% [33.3-37.8%], p < 0.0001). Women had a higher OS rate than men (5-year OS, 34% [95% CI; 31.4-36.7%] vs 27.7% [25.7-29.7%], p < 0.0001). The OS rate was lower in patients aged 40 and older than those under 40, and even lower in those over 65 (5-year OS for ages < 40, 40-64, 65-74, ≥ 75: 74.5% [95% CI; 69.3-79.0%] vs 47.5% [44.4-50.6%] vs 19.3% [16.8-22.0%] vs 7.3% [5.5-9.4%], respectively). This is the first paper to present large-scale data on survival and clinical characteristics in Japanese AML patients.